Orchestra BioMed adopts 2026 cash bonus plan and raises CEO, COO compensation
On February 12, 2026, Orchestra BioMed's board approved a 2026 cash bonus plan for all executive officers tied to BACKBEAT and Virtue SAB pivotal study milestones and financial and operating objectives. The board also raised base salaries for CEO Mr. Hochman (4%) and COO Mr. Sherman (10%) and increased their target bonus percentages, which shareholders may watch as the plan ties pay to clinical and financial goals.
Key points
- Up to 25% of annual bonuses may be paid in Q3 2026 based on mid-year metrics; up to 75% in Q1 2027 based on full-year performance.
- Mr. Hochman's base salary rises 4%, and his target bonus increases from 80% to 100% of base salary.
- Mr. Sherman's base salary rises 10%, and his target bonus increases from 80% to 90% of base salary.
- RSU awards will now vest in four equal 25% installments at 18, 24, 30 and 36 months.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.